<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308230">
  <stage>Registered</stage>
  <submitdate>16/07/2009</submitdate>
  <approvaldate>3/08/2009</approvaldate>
  <actrnumber>ACTRN12609000652279</actrnumber>
  <trial_identification>
    <studytitle>Safety and tolerability of the Traditional Chinese Medicine Formulation "GOPAC" in patients with advanced malignancy</studytitle>
    <scientifictitle>Phase I study of the Safety and Tolerability of the Traditional Chinese Medicine formulation "GOPAC" in patients with advanced malignancy</scientifictitle>
    <utrn />
    <trialacronym>GOPAC trial</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced malignancy (palliative)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>"GOPAC" is a traditional chinese herbal medicine proprietary formulation consisting of 5 herbs in a capsule formulation.
It is administered as a combination of 2 oral capsules: 
1. "Clone of Concord Sunchih GOPAC" (Ganoderma lucidum 140mg spore &amp; 100mg extract; Agrimonia eupatoria 75mg; Patrinia scabiosaefolia 75mg; Hedyotis diffusa 100mg; Cordyceps sinensis 10mg)
2. "Concord Vita-cordy"
(Cordyceps sinensis 400mg)

Duration of supplement: 6 wks
Mode Of Administration (MOA): oral capsule

Dose (dose escalation study):
1. Cohort 1: 2 capsules each three times a day (TDS)
2. Cohort 2: 3 capsules each TDS
3. Cohort 3: 4 capsules each TDS</interventions>
    <comparator>No comparator. 

3 treatment groups as it is a dose escalation study. 
As above (for 6 wks):

1. Cohort 1: 2 capsules each TDS
2. Cohort 2: 3 capsules each TDS
3. Cohort 3: 4 capsules each TDS</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase I: safety, as measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE V4.0)</outcome>
      <timepoint>Phase I: weekly measurements of adverse events (by NCI CTCAE V4.0) and bloods 
for 6 weeks of active therapy; then fortnightly for another 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Phase I: 
* patient tolerance (as measured by pill count, physician assessment)
* maximum tolerated dose (measured by dose limiting toxicity)</outcome>
      <timepoint>Phase I: end of 6 weeks of active therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Active malignancy (recurrent or metastatic)
* can swallow capsules WHOLE
* Fluent english or chinese
* not currently receiving chemotherapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inadequate organ function
Allergy to study ingredients (esp. mushrooms)
Eastern Cooperative Oncology performance group (ECOG PS) &gt; 3
Concurrent radiotherapy
Major comorbidities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Eligible patients for Phase I will be enrolled, and systematically allocated into treatment groups. No blinding for phase I trial.</concealment>
    <sequence>Nil</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Dose escalation study</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service</primarysponsorname>
    <primarysponsoraddress>Sydney Cancer Centre, 
Building 76
Concord Repatriation General Hospital
Hospital Road
Concord West 2139 NSW</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study looks at the safety and tolerability of the traditional chinese medicine formulation GOPAC in patients with advanced malignancy. 

Who is it for? 
You can join the study if you have cancer which has recurred or spread to distant sites and you are not currently receiving chemotherapy. 

Trial details: 
Participants will all receive GOPAC capsules for 6 weeks. Each week they will be monitored with questionnaires, blood tests and measurement of any toxic response. 
GOPAC is a traditional chinese herbal medicine formulation consisting of 5 herbs in a capsule formulation. It has few reported side effects.</summary>
    <trialwebsite>N/a</trialwebsite>
    <publication>Nil yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research &amp; Ethics Committee - Concord</ethicname>
      <ethicaddress>Concord Repatriation General Hospital 
Hospital Road
Concord West NSW 2139</ethicaddress>
      <ethicapprovaldate>22/06/2009</ethicapprovaldate>
      <hrec>09/CRGH/47</hrec>
      <ethicsubmitdate>18/03/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Stephen Clarke</name>
      <address>Sydney Cancer Centre, 
B76, Concord Repatriation General Hospital
Hospital Road
Concord West 2139 NSW</address>
      <phone>+61 2 9767 6775</phone>
      <fax>+61 2 9767 7603</fax>
      <email>sclarke@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Inger Olesen</name>
      <address>Sydney Cancer Centre, 
B76, Concord Repatriation General Hospital
Hospital Road
Concord West 2139 NSW</address>
      <phone>+61 2 9767 6354</phone>
      <fax>+61 2 9767 5764</fax>
      <email>iolesen@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Inger Olesen</name>
      <address>Sydney Cancer Centre, 
B76, Concord Repatriation General Hospital
Hospital Road
Concord West 2139 NSW</address>
      <phone>+61 2 9767 6800</phone>
      <fax>+61 2 9767 5764</fax>
      <email>iolesen@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>